Medicus Pharma Reports 73% Clearance in Basal Cell Carcinoma Phase 2 Trial | NewsOut

Biotech and healthcare investors: Medicus Pharma reported encouraging results from its Phase 2 clinical study evaluating SkinJect microneedle delivery of D-MNA and P-MNA for the treatment of basal cell carcinoma.

Reporting from the New York Stock Exchange, Jane King explains the trial demonstrated 73% clinical clearance and 40% histological clearance at day 57, representing the strongest treatment response observed in the study and suggesting many patients may potentially avoid immediate surgical procedures.

#MedicusPharma
#SkinJect
#BasalCellCarcinoma
#ClinicalTrials
#CancerResearch
#BiotechInnovation
#DrugDevelopment
#MicroneedleTechnology
#OncologyResearch
#HealthcareInvesting
#JaneKing
#NewsOut